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Bu with 2 nucleoside analogs ban be utilized to improve currently
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LONG-TERM SURVIVAL AFTER T-CELL DEPLETED ALLOGENEIC STEM
CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC
LEUKEMIA
Linker, A.1, Goldberg, J.D.1, Ratan, R.1, Jurcic, J.2, Barker, J.N.1, Castro-
Malaspina, H.1, Jakubowski, A.A.1, Jenq, R.1, Koehne, G.1,
Papadopoulos, E.1, van den Brink, M.R.M.1, Young, J.W.1, Boulad, F.3,
Kernan, N.A.3, O’Reilly, R.J.3, Small, T.N.3, Heller, G.4, Perales, M.-A.1
1Adult Bone Marrow Transplantation Service; 2Leukemia Service; 3Bone
Marrow Transplantation Service; 4Memorial Sloan-Kettering Cancer
Center, New York, NY
T-cell depleted allogeneic hematopoietic stem cell transplants
(TCD-HSCT) have demonstrated durable disease free survival
with a low risk of graft vs. host disease (GVHD) in patients with
AML, MDS and NHL.We investigated this approach in 60 consec-
utive adult patients with ALL who underwent TCD-HSCT from
May 1997 through December 2008. Patients received myeloablative
cytoreduction consisting of hyperfractionated total body irradiation
(1375-1500cGy), followed by thiotepa (10mg/kg) and either cyclo-
phosphamide (120mg/kg, n 5 22) or fludarabine (125mg/m2, n 5
38). No immunosuppressive agents were used post-HSCT. There
were 39 males and 21 females. The median age was 36 years (range,
18-63). Twenty-seven patients were in hematologic CR1, 18 in CR2,
11 in CR3 or greater, and 4 patients had relapsed or refractory dis-
ease. Baseline cytogenetics were classified as poor risk (n 5 26, in-
cluding Ph1 5 17), standard risk (n 5 26), good risk (n 5 4) or
non-evaluable (n 5 4). Forty-eight patients had a B-cell and 10
a T cell phenotype (multilineage 5 1, unknown 5 1). Bone marrow
grafts were depleted of T-cells by soybean lectin agglutination and
sheep erythrocyte rosette depletion and PBSC grafts underwent
CD341 positive selection using the ISOLEX 300i Magnetic Cell
Separator and sheep erythrocyte rosette depletion. Twenty-four pa-
tients received grafts from HLA matched related donors (MRD), 8
from a single allele disparate related donor (MMRD), 15 from
HLAmatched unrelated donors (MUD), 13 fromHLAmismatched
unrelated donors (MMUD).With a median follow-up of 8.4 months
(range 0.2-149 months), 5-year overall survival (OS) and progres-
sion-free-survival (PFS) were 45% and 30%, respectively. The re-
lapse rate was 30% in patients in CR at time of HSCT. The 4
patients with relapsed or refractory disease died of relapse (n 5 3)
or infection (n 5 1). Ten of 58 evaluable patients (17%) developed
grade 2-3 aGVHD post-HSCT (MRD 5 2, MUD 5 3, MMRD
5 4, MMUD 5 1); cGVHD occurred in 13% evaluable patients.
We examined factors that predict outcomes in patients with ALL,
and we found that only disease status at time of HSCT predicted
PFS (p \ 0.001). Pre-HSCT LDH was predictive of OS (p 5
0.047). No effect was observed for cytogenetics, WBC at diagnosis,
or presence of extramedullary disease. While TCD-HSCT does
provide acceptable OS and PFS without GVHD in adult patients
with ALL, relapse remains a limiting factor. Future studies focusing
on novel conditioning regimens and/or maintenance therapy are
warranted.264
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Introduction: Leukemic relapse following initial induction chemo-
therapy has been predicted independently by the rate of peripheral
blast clearance in adult AML and pediatric ALL. This early response
to therapy in de-novo acute leukemia may indicate in-vivo chemo-
sensitivity of malignant cells. No reports exist on whether blastresponse is predictive of relapse after myeloablative conditioning
for allogeneic hematopoietic stem cell transplantation (AlloHSCT).
Methods:We analyzed 69 patients with AML (n 5 47), MDS (n 5
17), and ALL (n5 5) who had circulating blasts prior to busulfan- or
TBI-based myeloablative AlloHSCT at a single academic center
from 1998 to 2009. Individual regression slopes for consecutive
values of circulating blasts were calculated throughout conditioning
chemotherapy. Relapse-free (RFS) and overall survival (OS) were es-
timated by Kaplan-Meier method and Cox proportional hazards
model.
Results: The median age of patients (49% males) was 47 years
(range, 20-62). 31 (45%) receivedmore than one prior chemotherapy
regimen; 31 (45%) had unrelated donor AlloHSCT; 14 (20%) re-
ceived TBI-based preparation; 34 (49%) relapsed after AlloHSCT.
50 (73%) patients were able to clear their circulating blasts within
median of 6.5 days (range, 2-10). Time to blast clearance was associ-
atedwith underlyingmalignancy (median of 4, 7, and 8 days for ALL,
MDS, and AML respectively, p\ 0.001) and myeloablative condi-
tioning (median of 4 days for TBI- vs. 8 days for busulfan-based
preparation, p \ 0.001). Median average slope of blast clearance
was -15.9 per day (range, -65.2 to 10.3). Neither velocity of blast de-
cline (p5 0.4) nor the number of days to circulating blast clearance (p
5 0.35) was predictive for time to disease relapse.More than one pre-
vious chemotherapy was associated with higher relapse rate (hazard
ratio [HR]5 2.5, p\0.01) andworseOS (HR5 2.2, p\0.01), while
receiving TBI-containing preparation portended poor OS (HR 5
2.3, p\ 0.01) in multivariable analysis.
Conclusions: The number of previous chemotherapies, but not the
slope of circulating blast decline during myeloablative conditioning
for AlloHSCT, predicted disease relapse and OS in patients with cir-
culating blasts.265
MOST PATIENTS WITH CBF LEUKEMIA WILL REQUIRE HSCT FOR LONG
TERM DISEASE CONTROL: RESULTS OF COHORT OF UNSELECTED
PATIENTS
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Patients with CBF-AML are regarded as having a favorable out-
come when treated with anthracycline-based induction chemother-
apy and multiple cycles of high-dose cytarabine consolidation.
Most data indicating the favorable prognosis of CBF-AML with
non-HSCT management originates from young selected patients
participating in clinical trials with scarce information on salvage
treatment. We performed a retrospective analysis of 30 consecutive
patients diagnosed with CBF-AML (14 with t(8;21) and 16 with inv
(16)) at a regional leukemia center over twelve years to assess long
term survival and the likelihood of therapeutic success without
ever requiring HSCT. We reviewed the charts of all patients with
CBF-AML (irrespective of other cytogenetic abnormalities) to ex-
tract demographic, treatment, and outcome information. Survival
status and subsequent treatments in other institutions were deter-
mined by contacting the patient, attending physician or review of
public death records. All patients were treated with curative intent
with anthracycline-based induction therapy, and 47% were on clin-
ical trials. Median age at diagnosis was 43 years (range 18-69). There
was 1 death during induction therapy and 22/29 patients (73.3%)
achieved a complete remission with initial induction therapy. Me-
dian follow up for survivors was 35.3 months (range 6.4-117.4)
with all survivors currently in remission. Overall 13 patients
(43.3%) have required some modality of HSCT. Six patients re-
ceived HSCT in CR1 due to perceived high risk of relapse (5 autol-
ogous, 1 allogeneic), none of which have relapsed. Among the 16
patients receiving non-transplant consolidation in CR1, 6 have sub-
sequently relapsed and required aHSCT (3 autologous, 3 allogeneic)
and 3 of these patients are alive 20.9-117.4 months from the initial
diagnosis. Seven patients received HSCT in CR2 or in relapse (4 au-
tologous, 3 allogeneic) and 6 of these patients are long-term survi-
vors. Estimated 5 year overall survival for the entire cohort is 58.8
1/- 10.8%, comparable to what has been described for younger pa-
tients entering clinical trials (Grimwade et al, 2010). The likelihood
Poster Session I S251of survival at 5 years without requiring HSCT was only 28.11/-
8.8%.We conclude that only a minority of patients with CBF leuke-
mia will be long term survivors relying exclusively on conventional
chemotherapy. Early use of HSCT for high-risk CBF-AML should
be pursued in clinical trials.266
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Introduction: Standard myeloablative conditioning combined bu-
sulphan (16 mg/kg) and cyclophosphamide (120 mg/kg) (BU-CY)
is associated with high non-hematologic toxicity, significantmorbid-
ity and mortality. Regimen combined fludarabin (125 mg/m2), bu-
sulphan (12 mg/kg) and thymoglobuline (6 mg/kg) (FLU-BU12-
TG) might be less toxic and safer despite the myeloablative dose of
busulphan. Retrospective study compared the results of allogeneic
SCT after those two regimens in the patients with AML.
Patients andMethods: 21 patients with AMLwere allografted after
BU-CY and 10 ones after FLU-BU12-TG. There were no differ-
ences between those groups in: the number of patients allografted
in complete remission of AML, gender and age of patients and do-
nors, the quality of graft and follow-up period. Significantly more
patients in the group of FLU-BU12-TG were allografted from un-
related (90% vs. 19%; P0,00018) and HLA mismatched donor
(50% vs. 0%; P0,0004). The incidence and risk of acute and chronic
graft versus host disease (GVHD), AML relapse, non-relapse
(NRM) and overall mortality, the probability of event-free (EFS)
and overall survival (OS) were analysed and compared in both con-
ditioning groups.
Results:No significant differences were found between the BU-CY
and FLU-BU12-TG in the incidence of acute (38% vs. 50%; P0,53)
or chronic GVHD (44% vs. 33%; P0,58), AML relapse (24% vs.
11%; P0,43), NRM (33% vs. 10%; P0,17), overall mortality (52%
vs. 20%; P0,087), the probability of 2-year EFS (50% vs. 89%;
P0,19) and OS (55% vs. 80%; P0,28).
Conclusion: Regimen FLU-BU12-TG seems to be a feasible
alternative approach to the patients allografted for AML and requir-
ing pretransplant cytoreduction but standard myeloablative condi-
tioning would be associated with the significant risk of severe
complications.LYMPHOMA/MULTIPLE MYELOMA
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MAINTENANCE THERAPY WITH LOW DOSE THALIDOMIDE, DEXAMETH-
ASONE AND CLARITHROMYCIN (BLT-D) FOLLOWING AUTOLOGOUS
TRANSPLANT (ASCT) FOR MULTIPLE MYELOMA (MM)
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Bensinger, W.1,2 1Fred Hutchinson Cancer Research Center, Seattle,
WA; 2University of Washington, Seattle, WA
Since relapse remains amajor problem after ASCT forMM, inves-
tigators have looked at the role of maintenance therapy post trans-
plant. It is not yet established which maintenance regimen is best
or the optimal duration for therapy.M. Coleman et al (Leuk&Lym-
phoma 43: 1777, 2002), pioneered a well tolerated regimen of BLT-
D with high CR/PR rates (93%) in MM patients. These results sug-
gested that BLT-D regimen may have a role as maintenance therapy
after ASCT.Twenty-seven patients (stage II, n-8; stage III, n5 19 by
Durie-Salmon criteria) were treated. Before ASCT, 52% had re-
ceived Thalidomide, 26% had received VAD, and 37% were treated
withmore than one regimen (range 2-4) prior tomobilization of stem
cells. At the time of ASCT, 20% were in CR/near CR. Following
ASCT, all patients received conditioning with melphalan 200mg/m2. After recovery from conditioning toxicity, between 30-120
days post ASCT (median 101 days (range 33-119), patients were
treated with Clarithromycin 250 mg po bid, dexamethasone 20 mg
po weekly, and thalidomide beginning dose 50 mg po daily days 1-
14, then increased to 100 mg po daily. After one year of combination
therapy, dexamethasone andClarithromycin were stopped. Thalido-
mide was given as long as tolerated until disease progression. Aspirin
and low dose coumadin were used as DVT prophylaxis. Six patients
(22%) discontinued thalidomide for progressive disease.Neuropathy
was the most common toxicity: 12 patients (44%) stopped because of
unimproved$ grade 2 toxicity and 7 (26%) required dose reduction
of thalidomide. One patient stopped therapy because of rash.Median
time to stoppingThalidomidewas 13.5months (range 6-42months).
Nine patients (33%) required dose reduction of dexamethasone. The
number of infections included: pneumonia (n5 3), upper respiratory
viral infection (n5 2), sinusitis (n5 1), and bronchitis (n5 3). Seven
patients have died due to: infection (n 5 1), MM (n 5 5), and com-
plications of second ASCT (n 5 1). As of 7/12/10, 20 patients
(74%) are alive and 13 (48%) are alive without disease progression.
Median follow-up is 59.5 months (38-73 months). In summary,
BLT-D can be given post ASCT. Peripheral neuropathy was the
most common significant toxicity that required patients to stop ther-
apy. With a median follow-up of 59.5 months from ASCT, 48% of
the patients are alive without evidence of disease progression and
74%are alive. Randomized studies to compare onemaintenance reg-
imen to another are needed post ASCT.268
MAINTENANCE THERAPYWITH LENALIDOMIDE, DEXAMETHASONE AND
CLARITHROMYCIN (BIRD) FOLLOWING AUTOLOGOUS TRANSPLANT
(ASCT) FOR MULTIPLE MYELOMA (MM)
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inson Cancer Research Center, Seattle, WA; 2University of Washington,
Seattle, WA
Since relapse remains a major cause for treatment failure after
ASCT for MM, the role of maintenance therapy has been studied.
Neither the best maintenance regimen nor optimal duration of ther-
apy post ASCT has been established. Niesvizky R et al (Blood 111:
1101-09, 2008) reported on the efficacy of BIRD as front-line ther-
apy for MM, with 90% objective response rate and manageable tox-
icities. Thus, it seemed reasonable to study such a regimen as
maintenance therapy post ASCT. Thirty-one patients (Stage I/II,
n5 13 and stage III, n5 18 by Durie-Salmon criteria) were treated.
Before ASCT, 81% received Thalidomide, 23% Lenalidomide, and
45% Bortezomib; 58% were treated with . 1 regimen (range 1-4)
prior to mobilization. Cytogenetic abnormalities included: poor
prognosis (23%), del13 by FISH (13%), t11,14 (10%), and tris 11/
11q (10%). PBSC were collected in 80% of patients off chemother-
apy/growth factor. At ASCT, 42% of patients were in PR, 6.5% had
SD, and 6.5% had progressive disease. All patients were conditioned
with melphalan 200mg/m2; one patient was treated after planned
tandem. At median of 113 days (range 49-133) and after recovery
from acute toxicity of ASCT, patients were treated with Clarithro-
mycin 250 mg po bid, Dexamethasone 20 mg po weekly, and Lena-
lidomide 25 mg po daily day 1-14 every 21 day cycles. After one year
of combination therapy, dexamethasone was tapered off and Clari-
thromycin was stopped. Lenalidomide was continued as long as tol-
erated until disease progression. All patients were treated daily with
coated aspirin (325 mg) for DVT prophylaxis. One patient devel-
oped DVT/PE. Five patients stopped therapy for disease progres-
sion and 11 stopped for significant toxicity (protracted . 30 days
peripheral neuropathy grade 3 (n 5 2), VZV/PCP/viral pneumonia
(n5 3), protracted neutropenia (n5 3), MDS 5q (n5 1), cellulitis (n
5 1), and leukocytic vasculitis (n 5 1)). Peripheral neuropathy and
neutropenia were most common non-infectious toxicities. As of 9/
2010, all patients remain alive and twenty patients (65%) remain
alive without disease progression; with median follow-up of 33
months (range 20-45) from transplant. In summary, BIRD can be
given post ASCT. Peripheral neuropathy and neutropenia are
most common non-infectious toxicities. With median follow-up of
33 months, all patients remain alive and 65% remain alive without
